Browse by Audience
Skip to content
Papers of the Week
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program.
Authors
Gottlieb AB, Burge R, Malatestinic WN, Zhu B, Zhao Y, McCormack J, Kimel M, Merola JFAbstract
Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and upon continuation for 24 weeks.